Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
19.43
-0.54 (-2.70%)
Sep 8, 2025, 11:23 AM - Market open
Upstream Bio Revenue
Upstream Bio had revenue of $937.00K in the quarter ending June 30, 2025, with 83.73% growth. This brings the company's revenue in the last twelve months to $2.72M, up 22.60% year-over-year. In the year 2024, Upstream Bio had annual revenue of $2.37M, down -0.42%.
Revenue (ttm)
$2.72M
Revenue Growth
+22.60%
P/S Ratio
286.23
Revenue / Employee
$52,365
Employees
52
Market Cap
1.05B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.37M | -10.00K | -0.42% |
Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
Dec 31, 2022 | 1.21M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionUPB News
- 13 hours ago - Upstream Bio, Inc. - Special Call - Seeking Alpha
- 6 days ago - Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - GlobeNewsWire
- 6 days ago - Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - GlobeNewsWire
- 4 weeks ago - Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress - GlobeNewsWire
- 2 months ago - Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) - GlobeNewsWire
- 3 months ago - Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewsWire
- 3 months ago - Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 - GlobeNewsWire
- 3 months ago - Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire